Rationale for B Cell Targeting in SLE

Overview

Journal Semin Immunopathol

Publisher Springer

Specialties Allergy & Immunology
Pathology

Date 2014 Apr 26

PMID 24763533

Citations 20

Authors

Inaki Sanz

Affiliations

Soon will be listed here.

Abstract

B cells are central pathogenic players in systemic lupus erythematosus and multiple other autoimmune diseases through antibody production as well as antibody independent function. At the same time, B cells are known to play important regulatory functions that may protect against autoimmune manifestations. Yet, the functional role of different B cell populations and their contribution to disease remain to be understood. The advent of agents that specifically target B cells, in particular anti-CD20 and ant-BLyS antibodies, have demonstrated the efficacy of this approach for the treatment of human autoimmunity. The analysis of patients treated with these and other B cell agents provides a unique opportunity to understand the correlates of clinical response and the significance of different B cell subsets. Here, we discuss this information and how it could be used to better understand SLE and improve the rational design of B cell-directed therapies in this disease.

Citing Articles

Human VH4-34 antibodies derived from B1 cells are more frequently autoreactive than VH4-34 antibodies derived from memory cells.

Ray M, Rothstein T Front Immunol. 2024; 14:1259827.

PMID: 38162664 PMC: 10754998. DOI: 10.3389/fimmu.2023.1259827.

VH2+ Antigen-Experienced B Cells in the Cerebrospinal Fluid Are Expanded and Enriched in Pediatric Anti-NMDA Receptor Encephalitis.

Monson N, Smith C, Greenberg H, Plumb P, Guzman A, Tse K J Immunol. 2023; 211(9):1332-1339.

PMID: 37712756 PMC: 10593502. DOI: 10.4049/jimmunol.2300156.

Analysis of a miR-148a Targetome in B Cell Central Tolerance.

Ma F, Zhan Y, Bartolome-Cabrero R, Ying W, Asano M, Huang Z Front Immunol. 2022; 13:861655.

PMID: 35634349 PMC: 9134011. DOI: 10.3389/fimmu.2022.861655.

Maternal Immunological Adaptation During Normal Pregnancy.

Abu-Raya B, Michalski C, Sadarangani M, Lavoie P Front Immunol. 2020; 11:575197.

PMID: 33133091 PMC: 7579415. DOI: 10.3389/fimmu.2020.575197.

Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects.

Soni C, Reizis B Front Immunol. 2019; 10:1601.

PMID: 31354738 PMC: 6637313. DOI: 10.3389/fimmu.2019.01601.

References

Stasi R, Cooper N, Del Poeta G, Stipa E, Evangelista M, Abruzzese E . Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008; 112(4):1147-50. DOI: 10.1182/blood-2007-12-129262. View

Ramos-Casals M, Sanz I, Bosch X, Stone J, Khamashta M . B-cell-depleting therapy in systemic lupus erythematosus. Am J Med. 2012; 125(4):327-36. PMC: 3925418. DOI: 10.1016/j.amjmed.2011.09.010. View

Moir S, Ho J, Malaspina A, Wang W, DiPoto A, OShea M . Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008; 205(8):1797-805. PMC: 2525604. DOI: 10.1084/jem.20072683. View

Vinuesa C, Sanz I, Cook M . Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol. 2009; 9(12):845-57. DOI: 10.1038/nri2637. View

Chan A . B cell immunotherapy in autoimmunity--2010 update. Mol Immunol. 2011; 48(11):1344-7. DOI: 10.1016/j.molimm.2010.11.021. View

van de Veerdonk F, Lauwerys B, Marijnissen R, Timmermans K, Di Padova F, Koenders M . The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011; 63(6):1507-16. DOI: 10.1002/art.30314. View

Lenert P, Brummel R, Field E, Ashman R . TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol. 2005; 25(1):29-40. DOI: 10.1007/s10875-005-0355-6. View

Stohl W, Hiepe F, Latinis K, Thomas M, Scheinberg M, Clarke A . Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012; 64(7):2328-37. PMC: 3350827. DOI: 10.1002/art.34400. View

Daridon C, Blassfeld D, Reiter K, Mei H, Giesecke C, Goldenberg D . Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther. 2010; 12(6):R204. PMC: 3046510. DOI: 10.1186/ar3179. View

10.

Jenks S, Sanz I . Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev. 2008; 8(3):209-13. PMC: 2693706. DOI: 10.1016/j.autrev.2008.07.047. View

11.

Griffin D, Rothstein T . Human b1 cell frequency: isolation and analysis of human b1 cells. Front Immunol. 2012; 3:122. PMC: 3360193. DOI: 10.3389/fimmu.2012.00122. View

12.

Miloslavsky E, Specks U, Merkel P, Seo P, Spiera R, Langford C . Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013; 65(9):2441-9. PMC: 4949954. DOI: 10.1002/art.38044. View

13.

Weller S, Reynaud C, Weill J . Splenic marginal zone B cells in humans: where do they mutate their Ig receptor?. Eur J Immunol. 2005; 35(10):2789-92. PMC: 2694967. DOI: 10.1002/eji.200535446. View

14.

Ettinger R, Sims G, Robbins R, Withers D, Fischer R, Grammer A . IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol. 2007; 178(5):2872-82. DOI: 10.4049/jimmunol.178.5.2872. View

15.

Tan E . Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989; 44:93-151. DOI: 10.1016/s0065-2776(08)60641-0. View

16.

Dorner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G . Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev. 2009; 9(2):82-9. DOI: 10.1016/j.autrev.2009.08.007. View

17.

Griffin D, Rothstein T . Human "orchestrator" CD11b(+) B1 cells spontaneously secrete interleukin-10 and regulate T-cell activity. Mol Med. 2012; 18:1003-8. PMC: 3459484. DOI: 10.2119/molmed.2012.00203. View

18.

Silverman G, Cappione A, Villano M, Ryan D, Insel R, Sanz I . Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest. 2001; 108(7):1061-70. PMC: 200949. DOI: 10.1172/JCI12462. View

19.

Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S . Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol. 2010; 38(4):633-41. DOI: 10.3899/jrheum.100729. View

20.

Wallace D, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K . Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford). 2013; 52(7):1313-22. DOI: 10.1093/rheumatology/ket129. View